Lung Cancer Research Foundation (LCRF) – LOI’s

Team Science Award on Advancing Therapies Toward CURING EGFR Mutated Lung Cancers
The overarching theme of the proposals should be centered around understanding and overcoming mechanisms of resistance to treatment for EGFRmut+ lung cancer.
Funding: max of $1.5M for 3 years (Non Profit)
https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-RFP-EGFR.pdf

Boehringer Ingelheim Early Investigator Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer
Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. Encourage applications on a wide variety of topics related to HER2-mutant lung cancer.
Funding: max of $250K over two years (Non Profit)
https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-LCRF-BI-HER2-early-career-RFP.pdf

Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations
Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. The proposal must include studies in patients with lung cancer harboring HER2 mutations.
Funding: max of $1.5M for 3 years (Non Profit)
https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-LCRF-BI-HER2-Team-Science-RFP.pdf

https://www.lungcancerresearchfoundation.org/research/funding-opportunities-late-2025/